A Phase 1, Multi-center, Open-label Study of IMGN779 Administered Intravenously in Adult Patients with Relapsed/Refractory CD33-positive Acute Myeloid Leukemia
You are being asked to take part in this study because you have leukemia that is refractory (has not responded to treatment) or relapsed (has come back after treatment). The goal of this clinical research study is to learn the highest tolerated dose of the experimental drug IMGN779 that can be given to patients with leukemia. The safety and effects of the drug will also be studied. Researchers also want to learn the best schedule by which the drug can be given. Participants receiving this consent form will receive the study drug every week (Schedule B). Participants receiving one of the other consent forms will receive the study drug every 2 weeks (Schedule A) or on Days 1 and 8 of each cycle (Schedule C). This is the first study using IMGN779 in humans.
Disease Group: Malignant neoplasms stated as primary lymphoid haematopoietic
Treatment Agent: IMGN779
Treatment Location: Both at MDACC & and Other Sites
Sponsor: ImmunoGen, Inc.
IRB Review and Approval Date: 03/31/2016
Recruitment Status: Open
Projected Accrual: 104
Information and next steps
Malignant neoplasms stated as primary lymphoid haematopoietic
For general questions about clinical trials: